Holen Sie sich die Stockscreener-App
10.19
0.00%
0.00
Schlusskurs vom Vortag:
$10.19
Offen:
$10.2
24-Stunden-Volumen:
264
Relative Volume:
0.01
Marktkapitalisierung:
$219.06M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+0.10%
1M Leistung:
+0.00%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$10.19
$10.20
1-Wochen-Bereich:
$10.13
$10.29
52-Wochen-Spanne:
$10.13
$10.35
Helix Acquisition Corp Iii Stock (HLXC) Company Profile
Firmenname
Helix Acquisition Corp Iii
Sektor
Branche
Telefon
-
Adresse
-
Compare HLXC vs CCXI, LION, XXI, CCCX, DMII
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HLXC
Helix Acquisition Corp Iii
|
10.19 | 219.06M | 0 | 0 | 0 | 0.00 |
|
CCXI
Churchill Capital Corp Xi
|
10.19 | 3.64B | 0 | 0 | 0 | 0.00 |
|
LION
Lionsgate Studios Corp
|
8.09 | 2.31B | 3.13B | -174.20M | -111.20M | -0.6937 |
|
XXI
Twenty One Capital Inc
|
6.40 | 2.01B | 0 | 0 | 0 | 0.00 |
|
CCCX
Churchill Capital Corp X
|
13.66 | 687.84M | 0 | 0 | 0 | 0.00 |
|
DMII
Drugs Made In America Acquisition Ii Corp
|
9.99 | 655.09M | 0 | 0 | 0 | 0.00 |
Helix Acquisition Corp Iii Aktie (HLXC) Neueste Nachrichten
A | Is Helix Acquisition Corp. II on track to beat earningsMarket Activity Recap & Capital Efficient Trading Techniques - mfd.ru
Can AIFER ride the EV waveQuarterly Profit Review & Free Long-Term Investment Growth Plans - mfd.ru
Newsroom - White & Case LLP
Helix Acquisition Corp. III completes $172.5 million IPO and private placement - Investing.com Nigeria
Helix Acquisition Corp. III Completes Initial Public Offering - TradingView
Finance Watch: SPACs Attempt A Comeback As IPO Market Shows Signs Of Life - Citeline News & Insights
With a Thin IPO Calendar, Hedge Funds Are Zeroing In on Biopharma - Institutional Investor
Helix Acquisition prices $150M initial public offering - MSN
Will Helix Acquisition Corp. II stock continue dividend increasesRate Cut & AI Forecast Swing Trade Picks - mfd.ru
Helix Acquisition Corp. III raises $172.5 million in Nasdaq IPO By Investing.com - Investing.com Nigeria
Helix Acquisition Corp III closes $172.5 million IPO By Investing.com - Investing.com South Africa
Helix Acquisition Corp. III closes $172.5 million IPO By Investing.com - Investing.com Australia
Helix Acquisition Corp. III raises $172.5 million in Nasdaq IPO - Investing.com
Helix Acquisition Corp. III closes $172.5 million IPO - Investing.com India
Helix Acquisition Corp. III Announces Closing of $172.5 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares - The Manila Times
SL Green Realty Corp. Announces Date of 2026 Annual Meeting of Stockholders - The Manila Times
Helix Acquisition Corp III closes $172.5 million IPO - Investing.com
White & Case advises Helix Acquisition Corp. III on upsized US$150 million IPO - White & Case LLP
New startup to develop a GLP-1 drug for addiction - statnews.com
Biotech investor Cormorant secures $150M for another SPAC deal - BioPharma Dive
Insider Buy: Does Unusual Machines Inc align with a passive investing strategyTrade Entry Report & Low Risk Investment Opportunities - baoquankhu1.vn
Helix Acquisition III Raises $150 Million, Targets Healthcare Sector - intellectia.ai
Helix Acquisition Corp. III Prices Upsized $150 Mln IPO - Nasdaq
Helix Acquisition Corp. III Announces Pricing of Upsized $150 Million Initial Public Offering - The Manila Times
U.S. IPO Weekly Recap: Equipment Rental Rises While Crypto Company Crashes In 2-IPO Week - Seeking Alpha
Day One was one of three parties interested in Mersana; Bihua Chen and Cormorant’s third SPAC - Endpoints News
Skild AI worth $14B, Airwallex's Series G, and BioMatrix makes a buy. - Axios
BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress - GlobeNewswire
BridgeBio Oncology stock initiated with Outperform rating at Oppenheimer - Investing.com
SPACs Line Up To Clear Biotech’s IPO Backlog - BioSpace
Helix Acquisition Corp. II Completes Merger with BridgeBio - The Globe and Mail
Cantor Fitzgerald initiates BridgeBio Oncology stock with Overweight rating By Investing.com - Investing.com Nigeria
BridgeBio’s oncology spinout sticks with SPAC to land on Nasdaq - Endpoints News
Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics - FinancialContent
BBOT Appoints Industry Veteran Uneek Mehra as Chief Financial Officer - Business Wire
BridgeBio Oncology's SPAC Merger Advances: SEC Clears Path for Novel Cancer Drug Development Platform - Stock Titan
Longevity Biotech Takes Root on Nasdaq With $180M SPAC Deal - BioSpace
Big Law Firms Wary of SPAC Rebound Seek to Get Paid This Time - Bloomberg Law News
Helix BioPharma (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") Secures Pre-IND Candidates LEUMUNA(TM) and GEMCEDA(TM) in Strategic Acquisition from the Laevoroc Group - TheNewswire
Helix Acquisition Corp. II SEC 10-Q Report - TradingView
German cancer antibody biotech eyes SPAC as route to Nasdaq - Fierce Biotech
Bay Area VC-funded life sciences companies raised over $5 billion in 2024 - The Business Journals
Checkpoint checks out | ApexOncoClinical Trials news and analysis - Oncology Pipeline
BridgeBio spin-out in SPAC deal to target RAS and PI3Kα malignancies - The Pharma Letter
BridgeBio spinout to go public in SPAC deal with Helix Acquisition Corp. II - MSN
BridgeBio Pharma's cancer-focused spinout plans $450 million deal to go public - The Business Journals
Life Sciences Hedge Fund Perceptive Preps a New SPAC - Institutional Investor
Helix Acquisition Corp. II Closes of $184 Million IPO - citybiz
Helix Acquisition Corp. II Prices of Upsized $160 Million IPO - citybiz
Cormorant Launches Second SPAC Following MoonLake Deal with $100M IPO - BioSpace
MoonLake Immunotherapeutics goes public via SPAC - Startupticker.ch
Finanzdaten der Helix Acquisition Corp Iii-Aktie (HLXC)
Es liegen keine Finanzdaten für Helix Acquisition Corp Iii (HLXC) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
0.29%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):